Sangamo BioSciences (SGMO) Shares are Down -0.45%

Sangamo BioSciences (SGMO) : During the past 4 weeks, traders have been relatively bearish on Sangamo BioSciences (SGMO), hence the stock is down -24.21% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.42% relative to the S&P 500. The 4-week change in the price of the stock is -23.92% and the stock has fallen -0.45% in the past 1 week.

Sangamo Biosciences Inc. has dropped 29.98% during the last 3-month period . Year-to-Date the stock performance stands at -51.92%. The stock has recorded a 20-day Moving Average of 17.92% and the 50-Day Moving Average is 22.36%.


Sangamo BioSciences (NASDAQ:SGMO): The stock opened at $4.39 on Friday but the bulls could not build on the opening and the stock topped out at $4.49 for the day. The stock traded down to $4.38 during the day, due to lack of any buying support eventually closed down at $4.39 with a loss of -0.68% for the day. The stock had closed at $4.42 on the previous day. The total traded volume was 440,870 shares.

Also, In a research note released to the investors, Janney Capital downgrades its rating on Sangamo BioSciences (NASDAQ:SGMO).The analysts at the brokerage house have a current rating of Neutral on the shares. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on August 4, 2016.

Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics. The Companys lead ZFP Therapeutic SB-728-T, a ZFN-modified autologous T-cell product is under development for the treatment of HIV/AIDS. The Companys clinical stage programs also include SB-728-HSPC for the treatment of HIV/AIDS, SB-BCLmR-HSPC to treat Beta-thalassemia major and CERE-110 for the treatment of Alzheimers disease. Its pre-clinical products include SB-913 for the treatment of Hunter Syndrome and SB-318 for the treatment of Hurler Syndrome.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.